Davies Charlotte, Holcombe Christopher, Skillman Joanna, Whisker Lisa, Hollingworth William, Conefrey Carmel, Mills Nicola, White Paul, Comins Charles, Macmillan Douglas, Fairbrother Patricia, Potter Shelley
Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, Bristol, UK
Linda McCartney Breast Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
BMJ Open. 2021 Apr 16;11(4):e046622. doi: 10.1136/bmjopen-2020-046622.
Approximately 40% of the 55 000 women diagnosed with breast cancer each year in the UK undergo mastectomy because they are considered unsuitable for standard breast-conserving surgery (BCS) due to tumour size or multiple tumour foci. Mastectomy can significantly impact women's quality of life, and only one in four women currently undergo immediate breast reconstruction (IBR).Level 2 oncoplastic breast-conserving surgery (OPBCS) combines removing the cancer with a range of plastic surgical volume replacement (eg, local perforator flaps) and volume displacement techniques (eg, therapeutic mammaplasty) that can extend the role of BCS and may allow some women not suitable for standard BCS to avoid mastectomy. High-quality research to determine whether OPBCS offers a safe and effective alternative to mastectomy±IBR is currently lacking. Preliminary work is needed to ensure a future large-scale study is feasible and well designed and addresses questions important to patients and the National Health Service.
Mixed methods will be used to inform feasibility and design of a future large-scale study comparing the clinical effectiveness and cost-effectiveness of OPBCS and mastectomy±IBR. It will have four parts: (1) a National Practice Questionnaire to determine current practice and provision of oncoplastic breast and reconstructive surgery in the UK; (2) a pilot multicentre prospective cohort study to explore the proportion of patients choosing OPBCS versus mastectomy, the proportion in OPBCS is successful and clinical and patient-reported outcomes of different techniques at 3 and 12 months postsurgery; (3) a qualitative interview study to explore patients' attitudes to different procedures, rationale for decision-making and perceptions of outcomes; and (4) design of the future study.All centres offering OPBCS and mastectomy in the UK will be invited to participate. Recruitment is planned to commence winter 2020 and continue for 12 months.
The study has ethical approval from the Wales Research Ethics Committee 6 National Research Ethics Service (REC Ref 20/WA/0225). Results will be presented at national and international meetings and published in peer-reviewed journals. We will work with patients to develop lay summaries and share these through patient groups and breast cancer charities.
ISRCTN18238549.
在英国,每年确诊的55000名乳腺癌女性患者中,约40%会接受乳房切除术,因为她们因肿瘤大小或多个肿瘤病灶而被认为不适合进行标准的保乳手术(BCS)。乳房切除术会对女性的生活质量产生重大影响,目前只有四分之一的女性会接受即刻乳房重建(IBR)。二级肿瘤整形保乳手术(OPBCS)将癌症切除与一系列整形手术的容积替代(如局部穿支皮瓣)和容积移位技术(如治疗性乳房成形术)相结合,这些技术可以扩大保乳手术的作用,并可能使一些不适合标准保乳手术的女性避免乳房切除术。目前缺乏高质量的研究来确定肿瘤整形保乳手术是否能为乳房切除术±即刻乳房重建提供一种安全有效的替代方案。需要开展初步工作,以确保未来的大规模研究可行且设计良好,并解决对患者和国民医疗服务体系至关重要的问题。
将采用混合方法为未来一项比较肿瘤整形保乳手术与乳房切除术±即刻乳房重建的临床有效性和成本效益的大规模研究提供可行性和设计依据。该研究将包括四个部分:(1)一份全国实践调查问卷,以确定英国目前肿瘤整形乳房手术和重建手术的实践情况和提供情况;(2)一项试点多中心前瞻性队列研究,以探讨选择肿瘤整形保乳手术与乳房切除术的患者比例、肿瘤整形保乳手术的成功率以及术后3个月和12个月不同技术的临床和患者报告结局;(3)一项定性访谈研究(探索患者对不同手术的态度、决策理由和对结局的看法);以及(4)未来研究的设计。英国所有提供肿瘤整形保乳手术和乳房切除术的中心都将被邀请参与。计划于2020年冬季开始招募,并持续12个月。
该研究已获得威尔士研究伦理委员会6国家研究伦理服务机构的伦理批准(REC编号:20/WA/0225)。研究结果将在国内和国际会议上公布,并发表在同行评审期刊上。我们将与患者合作编写通俗易懂的总结,并通过患者群体和乳腺癌慈善机构分享这些内容。
ISRCTN18238549。